Source link : https://www.newshealth.biz/health-news/early-improvement-in-prurigo-nodularis-with-il-31-antagonist-maintained-at-1-year/
SAN DIEGO — More than two-thirds of patients with prurigo nodularis obtained long-term relief from itching, skin lesions, and sleep disturbance with the interleukin (IL)-31 antagonist nemolizumab, according to the largest-ever trial in the disease. After 52 weeks of continuous treatment, 88.9% of patients had a ≥4-point improvement in pruritus score, and 81.5% had a […]
Author : News Health
Publish date : 2024-03-12 14:58:02
Copyright for syndicated content belongs to the linked Source.
in Health